‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response

Hung Ling Huang; Meng Rui Lee; Chih Hsin Lee; Jann Yuan Wang

doi:10.1016/j.cmi.2024.08.009

‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response

Hung Ling Huang
, Meng Rui Lee
, Chih Hsin Lee
, Jann Yuan Wang

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1482-1483
Number of pages	2
Journal	Clinical Microbiology and Infection
Volume	30
Issue number	11
DOIs	https://doi.org/10.1016/j.cmi.2024.08.009
Publication status	Published - Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.cmi.2024.08.009

Cite this

Huang, H. L., Lee, M. R., Lee, C. H., & Wang, J. Y. (2024). ‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response. Clinical Microbiology and Infection, 30(11), 1482-1483. https://doi.org/10.1016/j.cmi.2024.08.009

‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response. / Huang, Hung Ling; Lee, Meng Rui; Lee, Chih Hsin et al.
In: Clinical Microbiology and Infection, Vol. 30, No. 11, 11.2024, p. 1482-1483.

Research output: Contribution to journal › Letter › peer-review

Huang, HL, Lee, MR, Lee, CH & Wang, JY 2024, '‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response', Clinical Microbiology and Infection, vol. 30, no. 11, pp. 1482-1483. https://doi.org/10.1016/j.cmi.2024.08.009

@article{dd4f457311634fe89ea77789758f4d57,

title = "{\textquoteleft}One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial{\textquoteright} – author's response",

author = "Huang, \{Hung Ling\} and Lee, \{Meng Rui\} and Lee, \{Chih Hsin\} and Wang, \{Jann Yuan\}",

year = "2024",

month = nov,

doi = "10.1016/j.cmi.2024.08.009",

language = "English",

volume = "30",

pages = "1482--1483",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "11",

}

TY - JOUR

T1 - ‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population

T2 - a randomized controlled trial’ – author's response

AU - Huang, Hung Ling

AU - Lee, Meng Rui

AU - Lee, Chih Hsin

AU - Wang, Jann Yuan

PY - 2024/11

Y1 - 2024/11

UR - https://www.scopus.com/pages/publications/85204724147

UR - https://www.scopus.com/pages/publications/85204724147#tab=citedBy

U2 - 10.1016/j.cmi.2024.08.009

DO - 10.1016/j.cmi.2024.08.009

M3 - Letter

C2 - 39173876

AN - SCOPUS:85204724147

SN - 1198-743X

VL - 30

SP - 1482

EP - 1483

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 11

ER -

‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this